vice versa). Similar observations c an be made concerning the concept of specificity.
Merzenich lucidly-observes that central substitutions compound the consequences of misrouted axons at the periphery and may account for the paresthesia, phantom limb, and pain experienced by some amputees.
I would, however, by no means conclude that all changes are for the worse. The fact that the reorganizational capacity diminishes with aging parallels the clinical observation that comparable brain lesions recover better in early life than in adulthood.
Whatever the exact balance between plasticity and specificity, substitution is in no sense random or chaotic. Rats deprived of their vibrissae are able to explore with the fur hairs on the muzzle. If even these are destroyed, other fur hairs can substitute.
There appears to be a meaningful hierarchy of sensory candidates that can be recruited to serve the purposes of the central projection area. Clinical observations of this principle are not hard to find. Phocomelic children born without arms, as mentioned by Sherrington, often develop extraordinary abilities for painting, sewing, and other fine motor skills, using their feet and toes.
The understanding of this plasticity, which may provide a theoretical foundation for sensory therapy, will rest on a deeper knowledge of the physiological processes that have just begun to be unraveled. Key Largely on the basis of electrophysiological studies, three Glu-Asp receptor subtypes have been tentatively identified, each being named after an agonist to which it is differentially sensitive, N-methyl-n-aspartate (NMDA), quisqualate, and kainate. A fourth receptor subtype has also been described, the ar-aminophosphonobutyrate receptor, which unlike the conventional postsynaptic Glu-Asp excitatory receptor, may function as an inhibitory autoreceptor located presynaptically on axon terminals.
The discovery that certain ions (e.g., Mg'+) and antagonist molecules ( g e. ., n-2-amino-5-phosphonopentanoate and n-2-amino-7-phosphonoheptanoate) are highly specific in blocking the NMDA receptor (13) has facilitated research on this receptor, just as lack of specific antagonists has hampered research on the other receptor subtypes. Despite technical problems with the method, ["H]Glu has proven to be a useful ligand for autoradiographic mapping of Glu receptors, which are found widely distributed throughout the CNS with particularly high concentrations in regions thought to be heavily innervated by Glu fibers, including the hippocampus, cerebral cortex, striaturn, lateral septum, and several thalamic nuclei.
Neurotoxicity of Glu
It was first reported 15 years ago (3) and has repeatedly been demon- CVO) . This is a surprisingly fulminating type of pathological process that progresses from edematous changes in the first few minutes to end-stage neuronal necrosis within an hour or two.
It is disturbing that, before the addition of glutamate to prepared baby foods was discontinued, one jar of baby food contained enough glutamate to reach one quarter of the oral dose (in mg/kg body wt) that destroys nerve cells in the hypothalamus of infant mice. Yet, many other prepared foods, such as soups, still contain large amounts of added glutamate. While those artificial sweeteners that contain aspartic acid are not used in such high concentrations, it is nevertheless important to realize that the effects of glutamate and aspartate are additive in a oneto-one proportion.
The two agents are often consumed together because a meal containing supplemental glutamate may be accompanied by artificially sweetened drinks or desserts.
Excitatory mechanism
From molecular specificity studies, it is clear that those Glu analogues known to have neuroexcitatory activity reproduce CVO neurotoxic effects of Glu, that these analogues display a parallel order of potencies for their excitatory and toxic actions, that analogues lacking excitatory activity also lack neurotoxicity, and that specific antagonists of Glu-type excitatory activity effectively protect against Glu-type neurotoxicity (3, 6) .
By electron microscopy it has been shown that the toxic action of Glu and its analogues impinges selectively on dendritic and somal surfaces of the neuron that possess excitatory receptors through which the depolarizing effects of Glu putatively are mediated (3). These several observations led to the "excitotoxic" concept that a depolarization mechanism underlies Glu neurotoxicity and that the toxic action is mediated through dendrosomal synaptic receptors specialized for glutamergic (or aspartergic) transmission.
Role of specific ions
Excessive influx of Ca2+ into the depolarized neuron has been proposed as the mechanism by which excitotoxins induce cell death. Recently, however, it was shown (8, 10) that the acute toxic action of various excitotoxins, including Glu, on retinal or hippocampal neurons in vitro depends on the presence of Na+ and Cl-, but not Ca'+, in the incubation medium.
It appears, therefore, that the classical acutely fulminating excitotoxicity of Glu is explained by the excitant inducing a persistent depolarization of dendrosomal membranes. This, in addition to initial cation conductance changes, results in an unregulated influx of Cl-, balanced ionically by influx of Na+ and osmotically by uptake of cytolytic amounts of H,O. Other recent evidence, however, suggests that there may be two mechanisms by which excitotoxins induce cell death, one being Ca2+ independent and having the exceedingly acute pathophysiological characteristics just described and the other being a delayed form of cell death that may be Ca2+ dependent (1).
Systemic neurotoxicity and safety implications
Because the arcuate hypothalamic nucleus, a neuroendocrine regulatory center, is one of the CVO brain regions damaged, animals treated with Glu in infancy manifest multiple neuroendocrine disturbances and have an abnormal body habitus in adulthood.
The fully developed syndrome includes obesity, skeletal stunting, reproductive failure, and hypoplasia of the adenohypophysis and gonads, together with abnormally low hypothalamic, pituitary, or plasma levels of luteinizing hormone, growth hormone, and prolactin.
It has also been shown that a subtoxic dose of Glu or its potent analogue NMA, when administered subcutaneously to weanling or adult male rats, induces acute perturbations in several neuroendocrine axes, resulting in altered pituitary output of plasma hormones such as luteinizing hormone and growth hormone.
Similarly, it has been shown that a subtoxic dose of NMA induces an acute release of luteinizing hormone, follicle-stimulating hormone, and prolactin in adult female rhesus monkeys.
On the basis of these and related findings it is believed that excitotoxins, when present in moderately elevated concentrations in blood, can penetrate CVO zones of the hypothalamus and activate certain neurons that regulate pituitary hormonal outputs, This kind of neuropathological mechanism, although more subtle than brain damage, warrants consideration in the safety evaluation of these agents because repetitive perturbations in plasma hormone levels in preadult consumers could adversely influence growth and development.
In light of these and other findings reviewed elsewhere (4), the widespread use of excitotoxins, including Glu and Asp, as food additives has remained a controversial issue.
Research applications
Just as Glu and related amino acids locally excite neurons throughout the CNS when administered by microelectrophoresis, it has been shown in the past decade that direct injection of these agents into various CNS regions results in local Glu-type neuronal degeneration with each agent displaying a neurotoxic potency proportional to its known excitatory potency. In recent years, certain of these agents (kainic acid, ibotenic acid, or NMDA) have been injected into a wide variety of brain areas by numerous investigators, with good agreement that the type of lesion produced involves destruction of neuronal cell bodies with relative sparing of axons of passage.
In CNS lesioning studies, this type of lesion has advantages over electrolytic or surgical approaches that destroy all tissue components in the path of the lesion, including fiber tracts that interconnect brain regions unrelated to the targeted cell group. Thus Glu and its excitotoxic analogues are being increasingly used as axon-sparing lesioning agents for deciphering structurefunction relations throughout the CNS. In addition, excitotoxins have been used to develop animal models for studying certain human disease processes. Since the initial demonstration in 1976 (2) that kainate injection into the rat striatum reproduces neuropathological and biochemical changes characteristic of Huntington's disease, the kainate-injected rat striatum has been used by many investigators as a model for studying Huntington's disease. Although less potent than kainate, Glu induces the same neuropathological changes when injected into the rat striatum.
Thus it has been proposed that a defect affecting the Glu transmitter system and resulting in excessive stimulation of Glu receptors on striatal neurons (striatal neurons are massively innervated by the corticostriatal tract, which is thought to use Glu as transmitter) may be responsible for the loss of striatal neurons in Huntington's disease. In an ongoing long-term clinical study to test this hypothesis, baclofen, a drug that inhibits synaptic release of Glu, is being administered to Huntington's disease patients to see if it will retard progression of the illness (11).
Sulfite oxidase deficiency
Sulfite oxidase deficiency is a rare defect of amino acid metabolism that causes widespread degeneration of central neurons and symptoms of blindness and spastic quadriplegia leading to death in early childhood. An abnormal metabolite, cysteine-Ssulfonic acid, accumulates in body tissues of patients with this condition. The molecular structure of this compound resembles that of the potent excitotoxin homocysteic acid (Fig. 1) , and, when injected into rat brain, it causes acute degeneration of neurons (3). It seems likely, therefore, that an accumulation of this excitotoxin, endogenously produced in the CNS of patients with sulfite oxidase deficiency, may be responsible for the degeneration of neurons. The brain regions sustaining damage are among those thought to be heavily innervated by synaptic terminals that use Glu as transmitter. Moreover, by continuous electrical or pharmacological stimulation of specific Glu pathways, it is possible to reproduce this type of cytopathology in neural elements lying postsynaptic to Glu axon terminals. Anoxia is not involved, but even if it were, it would be difficult to explain how anoxia would induce only postsynaptic degeneration while preserving presynaptic axons.
These findings strongly support the hypothesis that neurodegenerative changes associated with human epilepsy result from persistent discharge activity in Glu pathways with consequent excessive release of Glu at synaptic receptors. The mechanism may be relatively simple; in addition to excessive Glu release, repetitive depolarization and repolarization of Glu terminals may usurp the energy resources required for reuptake and inactivation of Glu by the axon terminals and allow toxic concentrations to accumulate at the receptors, thus inducing excitotoxic
